Live Breaking News & Updates on Paion Ag

Stay updated with breaking news from Paion ag. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Investegate |PAION AG Announcements | PAION AG: PAION GRANTS EXCLUSIVE LICENSE TO CRISTÁLIA FOR DEVELOPMENT AND COMMERCIALIZATION OF REMIMAZOLAM IN LATIN AMERICA

Investegate announcements from PAION AG, PAION GRANTS EXCLUSIVE LICENSE TO CRISTÁLIA FOR DEVELOPMENT AND COMMERCIALIZATION OF REMIMAZOLAM IN LATIN AMERICA ....

United States , United Kingdom , South Korea , Minas Gerais , Produtos Quimicos Farmaceuticos Ltda , Ralf Penner , Jim Phillips , Ricardos Pacheco , Frankfurt Stock Exchange Prime Standard , Distribution Services , New Drug Application , Latin America , Latin American , Regulatory Announcements , Corporate News , Investegate Announcements , Investegate Company Announcements , Paion Ag , Qs And Eqs ,

Investegate |PAION AG Announcements | PAION AG: Preliminary announcement of the publication of financial reports according to Articles 114, 115, 117 of the WpHG [the German Securities Act]

Investegate announcements from PAION AG, Preliminary announcement of the publication of financial reports according to Articles 114, 115, 117 of the WpHG [the German Securities Act] ....

Rate Fix , Investegate Announcements , Investegate Company Announcements , Paion Ag , Qs And Eqs ,

Investegate |PAION AG Announcements | PAION AG: PAION AG ANNOUNCES CHANGE IN SUPERVISORY BOARD

Investegate announcements from PAION AG, PAION AG ANNOUNCES CHANGE IN SUPERVISORY BOARD ....

United Kingdom , South Korea , Sandoz Novartis , Irina Antonijevic , Michael Schlenk , Ralf Penner , Frankfurt Stock Exchange , Rd Committee , Supervisory Board , Prime Standard , Management Board , Annual General Meeting , General Manager , Investegate Announcements , Investegate Company Announcements , Paion Ag , Qs And Eqs ,

Investegate |PAION AG Announcements | PAION AG: ACACIA PHARMA LAUNCHES BYFAVO(TM) (REMIMAZOLAM) IN THE U.S. FOR PROCEDURAL SEDATION IN ADULTS UNDERGOING MEDICAL PROCEDURES LASTING 30 MINUTES OR LESS

PAION AG
ACACIA PHARMA LAUNCHES BYFAVO(TM) (REMIMAZOLAM) IN THE U.S. FOR PROCEDURAL SEDATION IN ADULTS UNDERGOING MEDICAL PROCEDURES LASTING 30 MINUTES OR LESS
DGAP-News: PAION AG
/ Key word(s): Product Launch
PAION AG: ACACIA PHARMA LAUNCHES BYFAVO(TM) (REMIMAZOLAM) IN THE U.S. FOR PROCEDURAL SEDATION IN ADULTS UNDERGOING MEDICAL PROCEDURES LASTING 30 MINUTES OR LESS
28.01.2021 / 07:06
The issuer is solely responsible for the content of this announcement.
PAION AG: ACACIA PHARMA LAUNCHES BYFAVO(TM) (REMIMAZOLAM) IN THE U.S. FOR PROCEDURAL SEDATION IN ADULTS UNDERGOING MEDICAL PROCEDURES LASTING 30 MINUTES OR LESS
- Approximately 40 million procedures take place annually in the U.S. that require the use of procedural sedation ....

South Korea , Mike Bolinder , Yichang Humanwell , Hana Pharm , Ralf Penner , Mckesson Medsurg , Jim Phillips , Us Drug Enforcement Administration , Specialty Pharma Company , Drug Administration , Frankfurt Stock Exchange Prime Standard , Cardinal Health , European Medicines Agency , Acacia Pharma , Enforcement Administration , Chief Executive Officer , Marketing Authorization Application , Southeast Asia , United Kingdom , Investegate Announcements , Investegate Company Announcements , Paion Ag , Eqs And , தெற்கு கொரியா , ஹனா பார்ம் , ரால்ஃப் பென்னர் ,

Investegate |PAION AG Announcements | PAION AG: PAION ANNOUNCES EXCLUSIVE LICENSING AGREEMENT WITH LA JOLLA PHARMACEUTICAL FOR GIAPREZA(TM) (ANGIOTENSIN II) AND XERAVA(TM) (ERAVACYCLINE) IN EUROPE

PAION AG
PAION ANNOUNCES EXCLUSIVE LICENSING AGREEMENT WITH LA JOLLA PHARMACEUTICAL FOR GIAPREZA(TM) (ANGIOTENSIN II) AND XERAVA(TM) (ERAVACYCLINE) IN EUROPE
DGAP-News: PAION AG
/ Key word(s): Agreement
PAION ANNOUNCES EXCLUSIVE LICENSING AGREEMENT WITH LA JOLLA PHARMACEUTICAL FOR GIAPREZA(TM) (ANGIOTENSIN II) AND XERAVA(TM) (ERAVACYCLINE) IN EUROPE
12.01.2021 / 13:42
PAION ANNOUNCES EXCLUSIVE LICENSING AGREEMENT WITH
LA JOLLA PHARMACEUTICAL FOR GIAPREZA(TM) (ANGIOTENSIN II) AND XERAVA(TM) (ERAVACYCLINE) IN EUROPE
- PAION in-licenses exclusive rights to commercialize GIAPREZA(TM) and XERAVA(TM) throughout Europe
- La Jolla Pharmaceutical Company to receive USD 22.5 million upfront payment, up to USD 109.5 million in commercial milestone payments, and double-digit tiered royalty payments ....

United Kingdom , South Korea , Larry Edwards , Deutschland Gmb , Ralf Penner , Jim Phillips , Specialty Pharma Company , Pinsent Masons , European Commission , Drug Administration , Frankfurt Stock Exchange Prime Standard , Jolla Pharmaceutical Company , Jolla Pharma , Committee For Medicinal Products Human , European Medicines Agency , Tetraphase Pharmaceuticals Inc , European Investment Bank , European Economic Area , Chief Executive Officer , Market Approval Application , Medicinal Products , Human Use , Destum Partners , Management Board , European Summary , Product Characteristics ,